Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Feb;39(2):329–333. doi: 10.1128/aac.39.2.329

Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin.

A van 't Veen 1, J W Mouton 1, D Gommers 1, J A Kluytmans 1, P Dekkers 1, B Lachmann 1
PMCID: PMC162536  PMID: 7726491

Abstract

The influence of a natural pulmonary surfactant on antibiotic activity was investigated to assess the possible use of exogenous surfactant as a vehicle for antibiotic delivery to the lung. The influence of surfactant on the bactericidal activity of amoxicillin was tested against Staphylococcus aureus and Streptococcus pneumoniae, and the influence of surfactant on the activities of ceftazidime and tobramycin was tested against Klebsiella pneumoniae, Pseudomonas aeruginosa, S. aureus, and S. pneumoniae. In vitro antibiotic activity was determined by killing curve studies in media with and without surfactant. Amoxicillin and ceftazidime activities were not changed in the presence of surfactant, except for a decreased killing rate of S. pneumoniae by ceftazidime in medium with additional rabbit serum. In contrast, killing curves with low concentrations of tobramycin (0.25x and 1x the MIC) showed a decreased level of activity of tobramycin against all pathogens tested in the presence of surfactant. With higher tobramycin concentrations (4x the MIC) killing rates were decreased less or were unchanged in the presence of surfactant. Concluding from the results of the study, both amoxicillin and ceftazidime can be combined with surfactant without the loss of activity. For mixing surfactant with tobramycin, dosages should be adjusted to overcome the partial inactivation of tobramycin by surfactant.

Full Text

The Full Text of this article is available as a PDF (236.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin D. R., Honeybourne D., Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother. 1992 Jun;36(6):1176–1180. doi: 10.1128/aac.36.6.1176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barry A. L., Reller L. B., Miller G. H., Washington J. A., Schoenknect F. D., Peterson L. R., Hare R. S., Knapp C. Revision of standards for adjusting the cation content of Mueller-Hinton broth for testing susceptibility of Pseudomonas aeruginosa to aminoglycosides. J Clin Microbiol. 1992 Mar;30(3):585–589. doi: 10.1128/jcm.30.3.585-589.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brain J. D., Knudson D. E., Sorokin S. P., Davis M. A. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res. 1976 Feb;11(1):13–33. doi: 10.1016/0013-9351(76)90107-9. [DOI] [PubMed] [Google Scholar]
  4. Bressolle F., de la Coussaye J. E., Ayoub R., Fabre D., Gomeni R., Saissi G., Eledjam J. J., Galtier M. Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: pharmacokinetics and absolute bioavailability. Antimicrob Agents Chemother. 1992 Jul;36(7):1404–1411. doi: 10.1128/aac.36.7.1404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brown R. B., Kruse J. A., Counts G. W., Russell J. A., Christou N. V., Sands M. L. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group. Antimicrob Agents Chemother. 1990 Feb;34(2):269–272. doi: 10.1128/aac.34.2.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bryant R. E., Hammond D. Interaction of purulent material with antibiotics used to treat Pseudomonas infections. Antimicrob Agents Chemother. 1974 Dec;6(6):702–707. doi: 10.1128/aac.6.6.702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Coonrod J. D., Varble R., Jarrells M. C. Species variation in the mechanism of killing of inhaled pneumococci. J Lab Clin Med. 1990 Sep;116(3):354–362. [PubMed] [Google Scholar]
  8. Coonrod J. D., Yoneda K. Detection and partial characterization of antibacterial factor(s) in alveolar lining material of rats. J Clin Invest. 1983 Jan;71(1):129–141. doi: 10.1172/JCI110741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Craven D. E., Kunches L. M., Kilinsky V., Lichtenberg D. A., Make B. J., McCabe W. R. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. Am Rev Respir Dis. 1986 May;133(5):792–796. [PubMed] [Google Scholar]
  10. Dahlberg A. E., Horodyski F., Keller P. Interaction of neomycin with ribosomes and ribosomal ribonucleic acid. Antimicrob Agents Chemother. 1978 Feb;13(2):331–339. doi: 10.1128/aac.13.2.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Eijking E. P., van Daal G. J., Tenbrinck R., Luijendijk A., Sluiters J. F., Hannappel E., Lachmann B. Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats. Intensive Care Med. 1991;17(8):475–478. doi: 10.1007/BF01690770. [DOI] [PubMed] [Google Scholar]
  12. Goldstein F. W., Acar J. Testing Staphylococcus aureus for resistance to beta-lactams. J Antimicrob Chemother. 1991 Apr;27(4):549–550. doi: 10.1093/jac/27.4.549. [DOI] [PubMed] [Google Scholar]
  13. Gommers D., Vilstrup C., Bos J. A., Larsson A., Werner O., Hannappel E., Lachmann B. Exogenous surfactant therapy increases static lung compliance, and cannot be assessed by measurements of dynamic compliance alone. Crit Care Med. 1993 Apr;21(4):567–574. doi: 10.1097/00003246-199304000-00019. [DOI] [PubMed] [Google Scholar]
  14. Hodson M. E., Penketh A. R., Batten J. C. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet. 1981 Nov 21;2(8256):1137–1139. doi: 10.1016/s0140-6736(81)90588-2. [DOI] [PubMed] [Google Scholar]
  15. Ilowite J. S., Gorvoy J. D., Smaldone G. C. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis. 1987 Dec;136(6):1445–1449. doi: 10.1164/ajrccm/136.6.1445. [DOI] [PubMed] [Google Scholar]
  16. Jalowayski A. A., Giammona S. T. The interaction of bacteria with pulmonary surfactant. Am Rev Respir Dis. 1972 Feb;105(2):236–241. doi: 10.1164/arrd.1972.105.2.236. [DOI] [PubMed] [Google Scholar]
  17. Jonsson S., Musher D. M., Goree A., Lawrence E. C. Human alveolar lining material and antibacterial defenses. Am Rev Respir Dis. 1986 Jan;133(1):136–140. doi: 10.1164/arrd.1986.133.1.136. [DOI] [PubMed] [Google Scholar]
  18. Kenny M. A., Pollock H. M., Minshew B. H., Casillas E., Schoenknecht F. D. Cation components of Mueller-Hinton agar affecting testing of Pseudomonas aeruginosa susceptibility to gentamicin. Antimicrob Agents Chemother. 1980 Jan;17(1):55–62. doi: 10.1128/aac.17.1.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kharasch V. S., Sweeney T. D., Fredberg J., Lehr J., Damokosh A. I., Avery M. E., Brain J. D. Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis. 1991 Oct;144(4):909–913. doi: 10.1164/ajrccm/144.4.909. [DOI] [PubMed] [Google Scholar]
  20. Klastersky J., Carpentier-Meunier F., Kahan-Coppens L., Thys J. P. Endotracheally administered antibiotics for gram-negative bronchopneumonia. Chest. 1979 May;75(5):586–591. doi: 10.1378/chest.75.5.586. [DOI] [PubMed] [Google Scholar]
  21. Laforce F. M., Boose D. S. Sublethal damage of Escherichia coli by lung lavage. Am Rev Respir Dis. 1981 Dec;124(6):733–737. doi: 10.1164/arrd.1981.124.6.733. [DOI] [PubMed] [Google Scholar]
  22. Laube B. L., Links J. M., LaFrance N. D., Wagner H. N., Jr, Rosenstein B. J. Homogeneity of bronchopulmonary distribution of 99mTc aerosol in normal subjects and in cystic fibrosis patients. Chest. 1989 Apr;95(4):822–830. doi: 10.1378/chest.95.4.822. [DOI] [PubMed] [Google Scholar]
  23. Le Conte P., Potel G., Peltier P., Horeau D., Caillon J., Juvin M. E., Kerguéris M. F., Bugnon D., Baron D. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis. 1993 May;147(5):1279–1282. doi: 10.1164/ajrccm/147.5.1279. [DOI] [PubMed] [Google Scholar]
  24. Levy J., Smith A. L., Kenny M. A., Ramsey B., Schoenknecht F. D. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J Infect Dis. 1983 Dec;148(6):1069–1076. doi: 10.1093/infdis/148.6.1069. [DOI] [PubMed] [Google Scholar]
  25. Liu M. Y., Wang L. M., Li E., Enhorning G. Pulmonary surfactant will secure free airflow through a narrow tube. J Appl Physiol (1985) 1991 Aug;71(2):742–748. doi: 10.1152/jappl.1991.71.2.742. [DOI] [PubMed] [Google Scholar]
  26. Lüllmann H., Vollmer B. An interaction of aminoglycoside antibiotics with Ca binding to lipid monolayers and to biomembranes. Biochem Pharmacol. 1982 Dec 1;31(23):3769–3773. doi: 10.1016/0006-2952(82)90291-x. [DOI] [PubMed] [Google Scholar]
  27. Mendelman P. M., Smith A. L., Levy J., Weber A., Ramsey B., Davis R. L. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis. 1985 Oct;132(4):761–765. doi: 10.1164/arrd.1985.132.4.761. [DOI] [PubMed] [Google Scholar]
  28. Mingeot-Leclercq M. P., Laurent G., Tulkens P. M. Biochemical mechanism of aminoglycoside-induced inhibition of phosphatidylcholine hydrolysis by lysosomal phospholipases. Biochem Pharmacol. 1988 Feb 15;37(4):591–599. doi: 10.1016/0006-2952(88)90130-x. [DOI] [PubMed] [Google Scholar]
  29. Montgomery A. B., Debs R. J., Luce J. M., Corkery K. J., Turner J., Brunette E. N., Lin E. T., Hopewell P. C. Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Lancet. 1987 Aug 29;2(8557):480–483. doi: 10.1016/s0140-6736(87)91794-6. [DOI] [PubMed] [Google Scholar]
  30. Potter J. L., Matthews L. W., Spector S., Lemm J. Complex formation between basic antibiotics and deoxyribonucleic acid in human pulmonary secretions. Pediatrics. 1965 Nov;36(5):714–720. [PubMed] [Google Scholar]
  31. RUBENIS M., KOZIJ V. M., JACKSON G. G. LABORATORY STUDIES ON GENTAMICIN. Antimicrob Agents Chemother (Bethesda) 1963;161:153–156. [PubMed] [Google Scholar]
  32. Ramsey B. W., Dorkin H. L., Eisenberg J. D., Gibson R. L., Harwood I. R., Kravitz R. M., Schidlow D. V., Wilmott R. W., Astley S. J., McBurnie M. A. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993 Jun 17;328(24):1740–1746. doi: 10.1056/NEJM199306173282403. [DOI] [PubMed] [Google Scholar]
  33. Reimer L. G., Stratton C. W., Reller L. B. Minimum inhibitory and bactericidal concentrations of 44 antimicrobial agents against three standard control strains in broth with and without human serum. Antimicrob Agents Chemother. 1981 Jun;19(6):1050–1055. doi: 10.1128/aac.19.6.1050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Saggers B. A., Lawson D. In vivo penetration of antibiotics into sputum in cystic fibrosis. Arch Dis Child. 1968 Aug;43(230):404–409. doi: 10.1136/adc.43.230.404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Tisdale J. E., Pasko M. T., Mylotte J. M. Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve. Antimicrob Agents Chemother. 1989 Sep;33(9):1500–1505. doi: 10.1128/aac.33.9.1500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Unertl K. E., Lenhart F. P., Forst H., Peter K. Systemic antibiotic treatment of nosocomial pneumonia. Intensive Care Med. 1992;18 (Suppl 1):S28–S34. doi: 10.1007/BF01752974. [DOI] [PubMed] [Google Scholar]
  37. Van Daal G. J., Bos J. A., Eijking E. P., Gommers D., Hannappel E., Lachmann B. Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):859–863. doi: 10.1164/ajrccm/145.4_Pt_1.859. [DOI] [PubMed] [Google Scholar]
  38. Van Golde L. M., Batenburg J. J., Robertson B. The pulmonary surfactant system: biochemical aspects and functional significance. Physiol Rev. 1988 Apr;68(2):374–455. doi: 10.1152/physrev.1988.68.2.374. [DOI] [PubMed] [Google Scholar]
  39. Washington J. A., 2nd, Snyder R. J., Kohner P. C., Wiltse C. G., Ilstrup D. M., McCall J. T. Effect of cation content of agar on the activity of gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa. J Infect Dis. 1978 Feb;137(2):103–111. doi: 10.1093/infdis/137.2.103. [DOI] [PubMed] [Google Scholar]
  40. Young L. S., Hewitt W. L. Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus. Antimicrob Agents Chemother. 1973 Dec;4(6):617–625. doi: 10.1128/aac.4.6.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Zimelis V. M., Jackson G. G. Activity of aminoglycoside antibiotics aganst Pseudomonas aeruginosa: specificity and site of calcium and magnesium antagonism. J Infect Dis. 1973 Jun;127(6):663–669. doi: 10.1093/infdis/127.6.663. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES